[go: up one dir, main page]

MX2016010051A - Composicion y metodo para ayudar a dormir. - Google Patents

Composicion y metodo para ayudar a dormir.

Info

Publication number
MX2016010051A
MX2016010051A MX2016010051A MX2016010051A MX2016010051A MX 2016010051 A MX2016010051 A MX 2016010051A MX 2016010051 A MX2016010051 A MX 2016010051A MX 2016010051 A MX2016010051 A MX 2016010051A MX 2016010051 A MX2016010051 A MX 2016010051A
Authority
MX
Mexico
Prior art keywords
composition
aiding sleep
formulation
aiding
sleep
Prior art date
Application number
MX2016010051A
Other languages
English (en)
Other versions
MX373821B (es
Inventor
Bo Chen Lan
Original Assignee
Sequential Medicine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequential Medicine Ltd filed Critical Sequential Medicine Ltd
Publication of MX2016010051A publication Critical patent/MX2016010051A/es
Publication of MX373821B publication Critical patent/MX373821B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe una formulación de liberación controlada para tratar trastornos del sueño o insomnio. La formulación se formula para liberar un compuesto o combinación de compuestos en secuencia en etapas múltiples.
MX2016010051A 2014-02-06 2015-02-04 Composición y método para ayudar a dormir. MX373821B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936566P 2014-02-06 2014-02-06
PCT/US2015/014393 WO2015120006A1 (en) 2014-02-06 2015-02-04 Composition and method for aiding sleep

Publications (2)

Publication Number Publication Date
MX2016010051A true MX2016010051A (es) 2017-05-04
MX373821B MX373821B (es) 2020-03-24

Family

ID=53753899

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010051A MX373821B (es) 2014-02-06 2015-02-04 Composición y método para ayudar a dormir.
MX2020003139A MX2020003139A (es) 2014-02-06 2016-08-03 Composicion y metodo para ayudar a dormir.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020003139A MX2020003139A (es) 2014-02-06 2016-08-03 Composicion y metodo para ayudar a dormir.

Country Status (21)

Country Link
US (2) US9427409B2 (es)
EP (2) EP3102189B1 (es)
JP (1) JP6338683B2 (es)
KR (1) KR101774721B1 (es)
CN (2) CN110604727A (es)
AU (1) AU2015214285B2 (es)
BR (1) BR112016017742A2 (es)
CA (1) CA2934595C (es)
DK (1) DK3102189T3 (es)
ES (1) ES2759452T3 (es)
HR (1) HRP20192119T8 (es)
HU (1) HUE047654T2 (es)
MX (2) MX373821B (es)
MY (1) MY177906A (es)
NZ (1) NZ720813A (es)
PL (1) PL3102189T3 (es)
PT (1) PT3102189T (es)
RS (1) RS59800B1 (es)
SG (1) SG10202004858TA (es)
TW (1) TWI730939B (es)
WO (1) WO2015120006A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
PT3102189T (pt) * 2014-02-06 2019-12-11 Bo Chen Lan Composição e método para melhorar o sono
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
JP7576905B2 (ja) * 2016-05-06 2024-11-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー バレリアン組成物及び関連方法
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
JP2022509759A (ja) * 2018-11-06 2022-01-24 シークエンシャル・メディシン・リミテッド 睡眠補助のための組成物および方法
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
CN110075302A (zh) * 2019-04-19 2019-08-02 陶燃 一种治疗抑郁和失眠的组合物及其用途
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
KR20250148613A (ko) 2023-02-03 2025-10-14 트리스 파마 인코포레이티드 저 나트륨 옥시베이트 밤마다 1회 투여 조성물
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016231A1 (de) * 1996-10-11 1998-04-23 Medichemie Ag Lorazepam und diphenhydramin enthaltendes schlafmittel
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
CA2368367A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
DE60003194T2 (de) * 1999-08-26 2004-06-17 Neurocrine Biosciences, Inc., San Diego Sedativ hypnotische zusammensetzungen mit gesteuerter freisetzung und diesbezügliche verfahren
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
AU2004287485A1 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
JP2008524332A (ja) * 2004-12-20 2008-07-10 コレジウム ファーマシューティカル， インク． 睡眠傷害のための医薬組成物
WO2006133349A2 (en) * 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
US20070020333A1 (en) * 2005-07-20 2007-01-25 Chin-Chih Chiang Controlled release of hypnotic agents
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
US20070190130A1 (en) * 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
WO2008075372A1 (en) * 2006-12-18 2008-06-26 Lupin Limited Controlled release dosage forms of zolpidem
US20080248106A1 (en) * 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US20080254121A1 (en) 2007-04-10 2008-10-16 Iomedix Sleep International Srl Multi-layer melatonin composition
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CA2767576C (en) * 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
IT1401142B1 (it) * 2010-07-26 2013-07-12 Ambros Pharma S R L Procedimento per la preparazione di compresse a rilascio controllato comprendenti melatonina
US20130078304A1 (en) * 2011-09-28 2013-03-28 Taiwan Biotech Co., Ltd. Controlled release formulation for treating sleep disorders
CN103550775B (zh) * 2013-10-18 2017-08-25 广州共禾医药科技有限公司 一种抗失眠组合物及其应用及利用该组合物制备的多相脉冲顿释制剂及其制备方法
PT3102189T (pt) * 2014-02-06 2019-12-11 Bo Chen Lan Composição e método para melhorar o sono

Also Published As

Publication number Publication date
DK3102189T3 (da) 2019-12-02
US20150216811A1 (en) 2015-08-06
HRP20192119T1 (hr) 2020-03-06
MX373821B (es) 2020-03-24
EP3102189A1 (en) 2016-12-14
US9427409B2 (en) 2016-08-30
JP2016536371A (ja) 2016-11-24
HRP20192119T8 (hr) 2020-08-21
CA2934595A1 (en) 2015-08-13
CA2934595C (en) 2022-06-21
SG10202004858TA (en) 2020-06-29
TWI730939B (zh) 2021-06-21
JP6338683B2 (ja) 2018-06-06
AU2015214285A1 (en) 2016-06-23
CN110604727A (zh) 2019-12-24
TW201538160A (zh) 2015-10-16
NZ720813A (en) 2021-12-24
KR101774721B1 (ko) 2017-09-04
EP3102189A4 (en) 2017-07-12
HK1222580A1 (zh) 2017-07-07
KR20160057479A (ko) 2016-05-23
AU2015214285B2 (en) 2020-07-23
WO2015120006A1 (en) 2015-08-13
PL3102189T3 (pl) 2020-05-18
BR112016017742A2 (pt) 2018-06-26
RS59800B1 (sr) 2020-02-28
CN105899194B (zh) 2019-10-25
PT3102189T (pt) 2019-12-11
HUE047654T2 (hu) 2020-05-28
CN105899194A (zh) 2016-08-24
MY177906A (en) 2020-09-25
EP3102189B1 (en) 2019-09-04
US20160346216A1 (en) 2016-12-01
MX2020003139A (es) 2020-07-28
ES2759452T3 (es) 2020-05-11
EP3632416A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
MX2016010051A (es) Composicion y metodo para ayudar a dormir.
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2018005696A (es) Tratamiento de la osteoartritis.
EA201691582A1 (ru) Новые фармацевтические препараты
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
MX2020004024A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
CO2017001884A2 (es) Polimorfos de selinexor
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
CU20160120A7 (es) Benzimidazol-2-aminas como inhibidores de midh1
ECSP14030779A (es) Inhibidores del nampt
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
DOP2016000120A (es) Nuevos inhibidores de dgat2
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
MX382116B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR099766A1 (es) Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos
CL2017000118A1 (es) Métodos y composiciones para tratar desórdenes relacionados con el vih
BR112016017087A8 (pt) forma cristalina alfa do composto monobenzoato a e seu método de preparação e composição farmacêutica compreendendo-a
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.

Legal Events

Date Code Title Description
FG Grant or registration